Efficacy of Body Weight Reduction on Sglt-2 Inhibitor in People with Type 2 Diabetes Mellitus

Presentation Number: MON 614
Date of Presentation: April 3rd, 2017

Su Jin Jeong*1, Jong Hwa Kim2 and Hyun A Cho3
1Sejongh general hospital, Bucheon, Korea, Democratic People's Republic of (North), 2sejong general hospital, Bucheon, Korea, Democratic People's Republic of (North), 3Sejong general hospital, Bucheon, Korea, Democratic People's Republic of (North)

Abstract

Objective We evaluated the efficacy and safety of body weight reduction of dapagliflozinin real practice with type 2 diabetes in Korea.

MethodsThis is a retrospective, observational study, data from 61 patients with12months of dapagliflozin (10mg once-daily) therapy were analyzed,visited one medical center from January 2015 to July 2016. We had been added to one of three ongoing treatment regimens: first group taking metformin (Group 1); second group taking metformin with sulfonylurea or dipeptidyl-peptidase IV (DPP-4) inhibitors or thiazolidinediones (Group 2); third group taking metformin and sulfonylurea with DPP-4inhibitors or thiazolidinediones (Group 3).

ResultsAfter 12 months, mean change from baseline body weight was -3.4±2.6 kg (P<0.001) for total, -3.4±3.1 kg (P<0.001) for group 1, -2.7±2.0 kg (P=0.008) for group 2,-4.0±2.3 kg (P<0.001) for group 3. In total, mean change from baseline SBP and DBP were -6.0±14 mmHg (P=0.001) and -3.4±7.7 mmHg (P=0.002) respectively. Patients who achieved body weight reduction of ≥5% after 12 months were classified in the responder group and<5% non-responder group. There were baseline fasting C-peptide level was higher inresponder group thannon-responder group (3.25±1.07ng/mL vs. 2.62±1.02 ng/mL, P=0.023). In total,reductions in HbA1c and PP2 levels were -0.61±0.82% (P<0.001) and -35.4±62 mg/dL (P<0.001) respectively. There were no serious adverse event including hypoglycemia in dapagliflozin group.

ConclusionsIn patients with type 2 diabetes, SGLT-2 inhibitorimproved glycemic control and reduced body weight reduction with safety of dapagliflozin.

 

Nothing to Disclose: SJJ, JHK, HAC